Portage Biotech Inc. (NASDAQ:PRTG – Get Rating) – Analysts at HC Wainwright lifted their Q3 2023 earnings per share estimates for Portage Biotech in a report issued on Thursday, December 1st. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.23) per share for the quarter, up from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Portage Biotech’s current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Portage Biotech’s Q4 2023 earnings at ($0.24) EPS, FY2023 earnings at ($0.67) EPS and FY2024 earnings at ($1.12) EPS.

A number of other research firms also recently commented on PRTG. Cantor Fitzgerald dropped their price objective on Portage Biotech from $26.00 to $18.00 in a report on Wednesday, November 30th. Oppenheimer dropped their price objective on Portage Biotech from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, November 30th.

Portage Biotech Trading Down 1.1 %

NASDAQ PRTG opened at $7.25 on Monday. The stock has a 50-day simple moving average of $6.49 and a 200 day simple moving average of $7.82. The company has a market capitalization of $122.85 million, a PE ratio of -7.25 and a beta of 1.37. Portage Biotech has a 12 month low of $4.62 and a 12 month high of $13.93.

Institutional Investors Weigh In On Portage Biotech

Several large investors have recently modified their holdings of PRTG. Goldman Sachs Group Inc. bought a new stake in shares of Portage Biotech in the second quarter worth about $79,000. Beacon Investment Advisory Services Inc. bought a new stake in shares of Portage Biotech in the second quarter worth about $80,000. Millennium Management LLC bought a new position in shares of Portage Biotech during the second quarter worth about $92,000. Dimensional Fund Advisors LP bought a new position in shares of Portage Biotech during the third quarter worth about $107,000. Finally, Citadel Advisors LLC bought a new position in shares of Portage Biotech during the second quarter worth about $137,000. 0.97% of the stock is currently owned by institutional investors.

By: NickPosted on Categories: BUSINESS